Literature DB >> 15657054

Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.

Marc D Jacobs1, James Black, Olga Futer, Lora Swenson, Brian Hare, Mark Fleming, Kumkum Saxena.   

Abstract

Pim-1 is an oncogene-encoded serine/threonine kinase primarily expressed in hematopoietic and germ cell lines. Pim-1 kinase was originally identified in Maloney murine leukemia virus-induced T-cell lymphomas and is associated with multiple cellular functions such as proliferation, survival, differentiation, apoptosis, and tumorigenesis (Wang, Z., Bhattacharya, N., Weaver, M., Petersen, K., Meyer, M., Gapter, L., and Magnuson, N. S. (2001) J. Vet. Sci. 2, 167-179). The crystal structures of Pim-1 complexed with staurosporine and adenosine were determined. Although a typical two-domain serine/threonine protein kinase fold is observed, the inter-domain hinge region is unusual in both sequence and conformation; a two-residue insertion causes the hinge to bulge away from the ATP-binding pocket, and a proline residue in the hinge removes a conserved main chain hydrogen bond donor. Without this hydrogen bond, van der Waals interactions with the hinge serve to position the ligand. The hinge region of Pim-1 resembles that of phosphatidylinositol 3-kinase more closely than it does other protein kinases. Although the phosphatidylinositol 3-kinase inhibitor LY294002 also inhibits Pim-1, the structure of the LY294002.Pim-1 complex reveals a new binding mode that may be general for Ser/Thr kinases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657054     DOI: 10.1074/jbc.M413155200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Regulation of Skp2 levels by the Pim-1 protein kinase.

Authors:  Bo Cen; Sandeep Mahajan; Marina Zemskova; Zanna Beharry; Ying-Wei Lin; Scott D Cramer; Michael B Lilly; Andrew S Kraft
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

Review 2.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

3.  Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Authors:  Susann Herzog; Matthias Alexander Fink; Kerstin Weitmann; Claudius Friedel; Stefan Hadlich; Sönke Langner; Katharina Kindermann; Tobias Holm; Andreas Böhm; Eskil Eskilsson; Hrvoje Miletic; Markus Hildner; Michael Fritsch; Silke Vogelgesang; Christoph Havemann; Christoph Alexander Ritter; Henriette Elisabeth Meyer zu Schwabedissen; Bernhard Rauch; Wolfgang Hoffmann; Heyo Klaus Kroemer; Henry Schroeder; Sandra Bien-Möller
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

Review 4.  The survival kinases Akt and Pim as potential pharmacological targets.

Authors:  Ravi Amaravadi; Craig B Thompson
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 5.  New players in TLR-mediated innate immunity: PI3K and small Rho GTPases.

Authors:  Monica Ruse; Ulla G Knaus
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  Exploring the specificity of the PI3K family inhibitor LY294002.

Authors:  Severine I Gharbi; Marketa J Zvelebil; Stephen J Shuttleworth; Tim Hancox; Nahid Saghir; John F Timms; Michael D Waterfield
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

Review 7.  Nuclear and mitochondrial signalling Akts in cardiomyocytes.

Authors:  Shigeki Miyamoto; Marta Rubio; Mark A Sussman
Journal:  Cardiovasc Res       Date:  2009-03-11       Impact factor: 10.787

8.  Targeting Pim Kinases and DAPK3 to Control Hypertension.

Authors:  David A Carlson; Miriam R Singer; Cindy Sutherland; Clara Redondo; Leila T Alexander; Philip F Hughes; Stefan Knapp; Susan B Gurley; Matthew A Sparks; Justin A MacDonald; Timothy A J Haystead
Journal:  Cell Chem Biol       Date:  2018-07-19       Impact factor: 8.116

9.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Authors:  Zuping Xia; Christian Knaak; Jian Ma; Zanna M Beharry; Campbell McInnes; Wenxue Wang; Andrew S Kraft; Charles D Smith
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

10.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

Authors:  Xiu Feng Hu; Jie Li; Scott Vandervalk; Zeping Wang; Nancy S Magnuson; Pei Xiang Xing
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.